CompletedEarly Phase 1

Immune Response to the COVID-19 Vaccine

United States20 participantsStarted 2021-06-07

Plain-language summary

Explore the effects on immune response to include a potential third vaccine for the cancer cohort.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. History of HIV or organ/bone marrow transplant
✕. Actively receiving immunotherapy
✕. On active, chronic immunosuppression (\>10 mg daily dose of prednisone equivalent)
✕. Currently incarcerated or residence of another state
✕. Speaks a language other than English.

Immune response

Timeframe: 3 months

NCT IDNCT04936997

SponsorUniversity of Arizona

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-08-25